Better Wages and Working Conditions: How States Should Tackle Noncompete Agreements, “TRAPs,” and Other Restraints On Worker Mobility
June 11, 2024 — The purpose of this memorandum is to provide model legislation and relevant context for state lawmakers seeking to protect workers, small businesses, and consumers from the harmful effects of noncompete agreements. Over the course of this memorandum, we describe what noncompete agreements are—including agreements that function as noncompetes—and describe best practices for banning them outright.
Written Comments for HHS, DOJ, and FTC’s RFI on Consolidation in Health Care Markets
June 5, 2024 — Economic Liberties submitted this comment in response to the Department of Justice (“DOJ”), Department of Health and Human Services (“HHS”), and Federal Trade Commission (“FTC”) joint request for information (“RFI”) regarding consolidation in health care markets.
Morgan’s Monopoly Digest – June 2024
June, 2024 — December version of Economic Liberties' monthly newsletter that covers the latest with the federal antitrust agencies — the Federal Trade Commission and the Department of Justice's Antitrust Division — and other big developments in competition policy.
Antimonopoly Proposals for the National Defense Authorization Act (NDAA)
May 29, 2024 — This memo lays out a roadmap for Congress to reintroduce competition back into the defense industrial base, into federal contracting, and into the markets for services offered to American servicemembers and veterans through this year's National Defense Authorization Act.
Comment to the FTC and HHS on the Role of GPOs and Drug Wholesalers in America’s Drug Shortage Crisis
April 30, 2024 — Economic Liberties submitted the attached comment in response to the Federal Trade Commission and the Department of Health and Human Services’ joint request for information regarding the role of group purchasing organizations (GPOs) and drug wholesalers in America’s ongoing drug shortage crisis. The comment explains how GPOs contribute to shortages by pushing the price of generic drugs lower, imposing restricting and inflexible contract terms on medical providers, and undermine competition in pharmaceutical markets.
Medicare Advantage and Vertical Consolidation in Health Care
April 28, 2024 — This paper details the causes and costs of the new frontier of vertical healthcare consolidation and offers a
set of solutions to address it.